e2 does not have an equivalent effect on multiple proteinopathies and it may sometimes promote a pathology (see for example Goldberg et al., 2020b on tauopathies) and, moreover, does not offer protection even when the protein constituents are similar to those on which it has an effect, namely 3R and 4R species of tau. The gene discussed is MAPT; the disease is proteostasis deficiencies.